Sound waves vs. cancer: large registry tracks HIFU outcomes
NCT ID NCT07645872
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry gathers real-world information from thousands of men treated with high-intensity focused ultrasound (HIFU) for prostate cancer using the Focal One device. The goal is to monitor safety and track cancer control through routine PSA tests and MRI scans. By collecting data from everyday medical practice, researchers hope to better understand how well this non-invasive treatment works outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- high-intensity focused ultrasound (HIFU)
- What this could lead to
- If the data show consistent safety and good cancer control, HIFU could become a standard, non-invasive option for treating prostate cancer.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results depend on routine care and may vary across centers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2023
- Expected to finish
-
Apr 2031
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients Being treated for prostate cancer with the Focal One device
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Being treated for prostate cancer with the Focal One device * Patient does not object and consent\* to the collection of clinical data in the registry Exclusion Criteria: * Patient deprived of liberty following a judicial or administrative decision * Patient under guardianship or curatorship \* if applicable according to local regulation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Clinique Nantes Atlantis
RECRUITINGNantes, 44000, France
-
Clinique Saint vincent
RECRUITINGBesançon, 25056, France
-
Hôpital Civil Colmar
RECRUITINGColmar, 68000, France
-
Hôpital Edouard Heriot
RECRUITINGLyon, 69000, France
-
Hôpital privé Aix en provence
RECRUITINGAix-en-Provence, 13080, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive missile aims at prostate cancer that spread
- New PET tracer targets ACP3 to spot prostate cancer
- Can a One-Week radiation course match four weeks for prostate cancer?
- Can a new PET tracer spot hidden prostate cancer spread?
- Can a gel cushion shield the rectum during prostate radiation?
- A scanner in the operating room could show surgeons exactly where prostate cancer remains